NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
Highlights ► NK cell activity is governed by balance of activating and inhibitory receptors. ► Different KIR molecules recognize groups of class I alleles. ► Their variegated expression leads to a repertoire of NK cells with different cytotoxicities. ► Allotransplantation demonstrated that KIR can b...
Gespeichert in:
| Veröffentlicht in: | Current opinion in immunology 2012-04, Vol.24 (2), p.239-245 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 245 |
|---|---|
| container_issue | 2 |
| container_start_page | 239 |
| container_title | Current opinion in immunology |
| container_volume | 24 |
| creator | Thielens, Ariane Vivier, Eric Romagné, François |
| description | Highlights ► NK cell activity is governed by balance of activating and inhibitory receptors. ► Different KIR molecules recognize groups of class I alleles. ► Their variegated expression leads to a repertoire of NK cells with different cytotoxicities. ► Allotransplantation demonstrated that KIR can be key for haematologic tumour control. ► Therapeutic approaches based on KIR blockade are currently tested in clinics. |
| doi_str_mv | 10.1016/j.coi.2012.01.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00685898v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0952791512000039</els_id><sourcerecordid>964196657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-5ecb321644f4c47b136a3271853160d4ac93df6af4ec676360c4e250c05780383</originalsourceid><addsrcrecordid>eNp9kc9v0zAYhi0EYmXwB3BBvsEOCZ9_xImZhDRVg1YrIDE4W67zBVzSuNhppf73c9RtBw6cLFnv-1h-XkJeMygZMPV-U7rgSw6Ml8BKAPaEzFhT6wJEzZ-SGeiKF7Vm1Rl5kdIGAKpKwHNyxjlXUnM9I7dfb6jDvqdfFnPqepsSXdK0Q-c772hEh7sxxETf3Sy_X3ygXQxbuvahD7-OdAy54QfvbE_9MGI84DD6MLwkzzrbJ3x1f56Tn5-uf8wXxerb5-X8alU42cixqNCtBWdKyk46Wa-ZUFbwmjWVYApaaZ0WbadsJ9GpWgkFTiKvwEFVNyAacU4uTtzftje76Lc2Hk2w3iyuVma6A1BN1ejmwHL27Sm7i-HvHtNotj5NH7cDhn0yWkmmlarqnGSnpIshpYjdI5qBmbSbjcnazaTdAMuPTPQ39_T9eovtY-PBcw5cngKYfRw8RpOcx8Fh67Pj0bQZ-D_8x3_aD97_4BHTJuzjkEUbZlLumNtp92l2xvPkILS4A2jHo-s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>964196657</pqid></control><display><type>article</type><title>NK cell MHC class I specific receptors (KIR): from biology to clinical intervention</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Thielens, Ariane ; Vivier, Eric ; Romagné, François</creator><creatorcontrib>Thielens, Ariane ; Vivier, Eric ; Romagné, François</creatorcontrib><description>Highlights ► NK cell activity is governed by balance of activating and inhibitory receptors. ► Different KIR molecules recognize groups of class I alleles. ► Their variegated expression leads to a repertoire of NK cells with different cytotoxicities. ► Allotransplantation demonstrated that KIR can be key for haematologic tumour control. ► Therapeutic approaches based on KIR blockade are currently tested in clinics.</description><identifier>ISSN: 0952-7915</identifier><identifier>EISSN: 1879-0372</identifier><identifier>DOI: 10.1016/j.coi.2012.01.001</identifier><identifier>PMID: 22264929</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Histocompatibility Antigens Class I - immunology ; Histocompatibility Antigens Class I - metabolism ; Humans ; Immunology ; Immunotherapy ; Life Sciences ; Ligands ; Neoplasms - immunology ; Neoplasms - therapy ; Receptors, Natural Killer Cell - immunology ; Receptors, Natural Killer Cell - metabolism ; Signal Transduction</subject><ispartof>Current opinion in immunology, 2012-04, Vol.24 (2), p.239-245</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-5ecb321644f4c47b136a3271853160d4ac93df6af4ec676360c4e250c05780383</citedby><cites>FETCH-LOGICAL-c484t-5ecb321644f4c47b136a3271853160d4ac93df6af4ec676360c4e250c05780383</cites><orcidid>0000-0001-7022-8287</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0952791512000039$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22264929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00685898$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Thielens, Ariane</creatorcontrib><creatorcontrib>Vivier, Eric</creatorcontrib><creatorcontrib>Romagné, François</creatorcontrib><title>NK cell MHC class I specific receptors (KIR): from biology to clinical intervention</title><title>Current opinion in immunology</title><addtitle>Curr Opin Immunol</addtitle><description>Highlights ► NK cell activity is governed by balance of activating and inhibitory receptors. ► Different KIR molecules recognize groups of class I alleles. ► Their variegated expression leads to a repertoire of NK cells with different cytotoxicities. ► Allotransplantation demonstrated that KIR can be key for haematologic tumour control. ► Therapeutic approaches based on KIR blockade are currently tested in clinics.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Histocompatibility Antigens Class I - immunology</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Receptors, Natural Killer Cell - immunology</subject><subject>Receptors, Natural Killer Cell - metabolism</subject><subject>Signal Transduction</subject><issn>0952-7915</issn><issn>1879-0372</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9v0zAYhi0EYmXwB3BBvsEOCZ9_xImZhDRVg1YrIDE4W67zBVzSuNhppf73c9RtBw6cLFnv-1h-XkJeMygZMPV-U7rgSw6Ml8BKAPaEzFhT6wJEzZ-SGeiKF7Vm1Rl5kdIGAKpKwHNyxjlXUnM9I7dfb6jDvqdfFnPqepsSXdK0Q-c772hEh7sxxETf3Sy_X3ygXQxbuvahD7-OdAy54QfvbE_9MGI84DD6MLwkzzrbJ3x1f56Tn5-uf8wXxerb5-X8alU42cixqNCtBWdKyk46Wa-ZUFbwmjWVYApaaZ0WbadsJ9GpWgkFTiKvwEFVNyAacU4uTtzftje76Lc2Hk2w3iyuVma6A1BN1ejmwHL27Sm7i-HvHtNotj5NH7cDhn0yWkmmlarqnGSnpIshpYjdI5qBmbSbjcnazaTdAMuPTPQ39_T9eovtY-PBcw5cngKYfRw8RpOcx8Fh67Pj0bQZ-D_8x3_aD97_4BHTJuzjkEUbZlLumNtp92l2xvPkILS4A2jHo-s</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Thielens, Ariane</creator><creator>Vivier, Eric</creator><creator>Romagné, François</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-7022-8287</orcidid></search><sort><creationdate>20120401</creationdate><title>NK cell MHC class I specific receptors (KIR): from biology to clinical intervention</title><author>Thielens, Ariane ; Vivier, Eric ; Romagné, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-5ecb321644f4c47b136a3271853160d4ac93df6af4ec676360c4e250c05780383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Histocompatibility Antigens Class I - immunology</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Receptors, Natural Killer Cell - immunology</topic><topic>Receptors, Natural Killer Cell - metabolism</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thielens, Ariane</creatorcontrib><creatorcontrib>Vivier, Eric</creatorcontrib><creatorcontrib>Romagné, François</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Current opinion in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thielens, Ariane</au><au>Vivier, Eric</au><au>Romagné, François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NK cell MHC class I specific receptors (KIR): from biology to clinical intervention</atitle><jtitle>Current opinion in immunology</jtitle><addtitle>Curr Opin Immunol</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>24</volume><issue>2</issue><spage>239</spage><epage>245</epage><pages>239-245</pages><issn>0952-7915</issn><eissn>1879-0372</eissn><abstract>Highlights ► NK cell activity is governed by balance of activating and inhibitory receptors. ► Different KIR molecules recognize groups of class I alleles. ► Their variegated expression leads to a repertoire of NK cells with different cytotoxicities. ► Allotransplantation demonstrated that KIR can be key for haematologic tumour control. ► Therapeutic approaches based on KIR blockade are currently tested in clinics.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>22264929</pmid><doi>10.1016/j.coi.2012.01.001</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7022-8287</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-7915 |
| ispartof | Current opinion in immunology, 2012-04, Vol.24 (2), p.239-245 |
| issn | 0952-7915 1879-0372 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00685898v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Allergy and Immunology Animals Histocompatibility Antigens Class I - immunology Histocompatibility Antigens Class I - metabolism Humans Immunology Immunotherapy Life Sciences Ligands Neoplasms - immunology Neoplasms - therapy Receptors, Natural Killer Cell - immunology Receptors, Natural Killer Cell - metabolism Signal Transduction |
| title | NK cell MHC class I specific receptors (KIR): from biology to clinical intervention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T16%3A24%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NK%20cell%20MHC%20class%20I%20specific%20receptors%20(KIR):%20from%20biology%20to%20clinical%20intervention&rft.jtitle=Current%20opinion%20in%20immunology&rft.au=Thielens,%20Ariane&rft.date=2012-04-01&rft.volume=24&rft.issue=2&rft.spage=239&rft.epage=245&rft.pages=239-245&rft.issn=0952-7915&rft.eissn=1879-0372&rft_id=info:doi/10.1016/j.coi.2012.01.001&rft_dat=%3Cproquest_hal_p%3E964196657%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=964196657&rft_id=info:pmid/22264929&rft_els_id=S0952791512000039&rfr_iscdi=true |